Aperture will advance APRTX-001 as a potential treatment for ALS and frontotemporal dementia, with possible expansion for use ...

A new pill for treating dementia is delivering promising "topline" results in early-stage clinical trials, according to a ...

A promising new treatment, VES001, for frontotemporal dementia (FTD) has successfully cleared its first major safety hurdle in early-stage clinical trials.

Lucid Capital analyst Elemer Piros initiated coverage of Passage Bio (PASG) with a Buy rating and $68 price target Passage Bio, which has ...

Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on ...

Are you or a loved one navigating a diagnosis that feels misunderstood? Frontotemporal Degeneration (FTD) is the most common ...

Both microtubule-binding protein tau and RNA-binding protein TDP-43 have been associated with neurodegenerative diseases, such as Alzheimer’s disease, including in co-pathological deposition with each ...

ProMIS Neurosciences Inc. , a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that its ...